Zhengye Biotechnology Holding Ltd
ZYBTHealthcare·Drug Manufacturers - Specialty & Generic·China·Nano·NASD·Nov 11 • 3:59 PM ET
1.52-0.02 (-1.30%)
2026-11-12 05:37 CET
Market cap
45.18 USD m
Revenue, TTM
16.18 USD m
Net income, TTM
-9.74 USD m
Free cash flow, TTM
1.73 USD m
EPS diluted, TTM
-0.21
P/E
-
Price
ZYBT against its 20, 50 and 200-day averages2050200
81.0% under the 52-week high of 8.01 on 20 Jul 2026. 52-week low 0.62 on 2 Jul 2026. Last 15 sessions, 35.9% high to low
Volume 0.04× normal · the line is the 50-bar volume average
Profile
ZYBT52-week range, 12% of the way up
0.628.01
Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. It offers a range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company was founded on March 24, 2023 and is headquartered in Jilin City, China.
| Employees | 269 |
|---|---|
| IPO | Jan 07, 2025 |
| Beta | -2.39 |
| ATR, 14d | 0.15 |
| Rel volume | 0.04 |
| Short float | 0.40% |
| Insider own | 74.09% |
| Inst own | 0.29% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 45.19M |
| Enterprise Value | 56.64M |
| Income | -9.74M |
| Sales | 16.18M |
| Book/sh | 0.75 |
| Cash/sh | 0.25 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 269 |
| IPO | Jan 07, 2025 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | 2.79 |
| P/B | 2.01 |
| P/C | 6.08 |
| P/FCF | 26.12 |
| EV/EBITDA | - |
| EV/Sales | 3.50 |
| Quick Ratio | 0.80 |
| Current Ratio | 1.14 |
| Debt/Eq | 0.30 |
| LT Debt/Eq | 0.04 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -0.21 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | - - |
| Sales past 3/5Y | -25.18% -16.43% |
| EPS Y/Y TTM | -717.42% |
| Sales Y/Y TTM | -37.53% |
| EPS Q/Q | -2195.59% |
| Sales Q/Q | -40.44% |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 74.09% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 0.29% |
| Inst Trans | -1.27% |
| ROA | -14.98% |
| ROE | -26.09% |
| ROIC | -26.28% |
| Gross Margin | 20.41% |
| Oper. Margin | -60.73% |
| Profit Margin | -60.22% |
| SMA20 | 5.78% |
| SMA50 | 7.49% |
| SMA200 | 29.89% |
| Trades | - |
Technical
| Shs Outstand | 29.73M |
|---|---|
| Shs Float | 7.70M |
| Short Float | 0.40% |
| Short Ratio | 0.05 |
| Short Interest | 0.03M |
| 52W High | 8.01 -81.02% |
| 52W Low | 0.62 146.95% |
| Volatility | 8.61% 9.55% |
| ATR (14) | 0.15 |
| RSI (14) | 56.16 |
| Beta | -2.39 |
| Rel Volume | 0.04 |
| Avg Volume | 607.29K |
| Volume | 22,767 |
Performance
| Perf Week | 10.95% |
|---|---|
| Perf Month | 2.70% |
| Perf Quarter | -0.65% |
| Perf Half Y | 58.45% |
| Perf YTD | 32.17% |
| Perf Year | -28.30% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | - |
| Target Price | - |
| Prev Close | 1.54 |
| Price | 1.52 |
| Change % | -1.30% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ZTS | Zoetis Inc | 33.55B |
| ELAN | Elanco Animal Health Inc | 13.24B |
| PAHC | Phibro Animal Health Corp | 1.43B |
| BGM | BGM Group Ltd | 107.50M |
| ICCC | Immucell Corp | 92.54M |
| CPHI | China Pharma Holdings Inc | 23.37M |
| UPC | Universe Pharmaceuticals INC | 7.89M |
| NEOG | Neogen Corp | 2.53B |
| JAGX | Jaguar Health Inc | 6.44M |
| IDXX | Idexx Laboratories Inc | 55.35B |
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| No annual earnings. | |||||
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | 0.128 | 0.147 | 0.094 | 0.033 | -0.205 |
|---|---|---|---|---|---|
| Period | 2021 | 2022 | 2023 | 2024 | 2025 |
| EPS, quarterly | |||||
| Period | |||||
| Sales, annual | 33.192 | 38.652 | 29.873 | 25.894 | 16.187 |
| Period | 2021 | 2022 | 2023 | 2024 | 2025 |
| Sales, quarterly | |||||
| Period | |||||
| Shares, annual | 47.166 | 47.166 | 47.166 | 47.166 | 47.391 |
| Period | 2021 | 2022 | 2023 | 2024 | 2025 |
| Shares, quarterly | |||||
| Period |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|---|
| Total Revenue | 16.18 | 16.19 | 25.89 | 29.87 | 38.65 | 33.19 |
| Cost of Goods Sold Incl. D&A | 12.87 | 12.87 | 13.21 | 11.54 | 15.85 | 13.75 |
| Gross Profit | 3.30 | 3.32 | 12.69 | 18.33 | 22.80 | 19.44 |
| Selling, General and Administrative Excl. Other | 13.13 | 13.13 | 10.40 | 10.56 | 12.88 | 11.08 |
| Research and Development | 2.51 | 2.51 | 1.78 | 1.68 | 1.99 | 1.76 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.82 | -9.81 | 2.28 | 7.77 | 9.92 | 8.36 |
| Interest Expense | 0.47 | 0.47 | 0.56 | 0.62 | 0.42 | 0.16 |
| Unusual Expense | -0.02 | -0.02 | 0.00 | 1.42 | 0.14 | 0.24 |
| Net Income Before Taxes | -10.01 | -10.00 | 2.00 | 6.18 | 9.49 | 8.23 |
| Income Taxes | 1.57 | 1.54 | 0.13 | 0.88 | 1.21 | 1.02 |
| Consolidated Net Income | -11.58 | -11.54 | 1.87 | 5.29 | 8.28 | 7.20 |
| Net Income From Continuing Operations | -9.74 | -9.71 | 1.57 | 4.44 | 6.94 | 6.04 |
| Net Income | -9.74 | -9.71 | 1.57 | 4.44 | 6.94 | 6.04 |
| EPS (Recurring) | -0.21 | -0.21 | 0.03 | 0.12 | 0.15 | 0.13 |
| EPS (Basic, Before Extraordinaries) | -0.21 | -0.20 | 0.03 | 0.09 | 0.15 | 0.13 |
| EPS (Diluted) | -0.21 | -0.20 | 0.03 | 0.09 | 0.15 | 0.13 |
| EBITDA | -6.21 | -6.20 | 5.61 | 11.11 | 12.71 | 10.84 |
| Non-Operating Income (Expense) | 0.27 | 0.27 | 0.28 | 0.45 | 0.14 | 0.27 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price To Sales Ratio | 3.37 | 3.36 | - | - | - | - |
| Gross Margin | 20.41 | 20.51 | 48.99 | 61.35 | 58.98 | 58.58 |
| Operating Margin | -60.73 | -60.59 | 8.82 | 26.00 | 25.67 | 25.18 |
| Net Margin | -60.22 | -59.97 | 6.07 | 14.86 | 17.96 | 18.20 |
| Shares Outstanding | 47.39 | 47.39 | 47.17 | 47.17 | 47.17 | 47.17 |
| Market Capitalization | 45.18 | 45.18 | 53.55 | - | - | - |
Income statement, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 | 2022S2 | 2022S1 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7.58 | 8.59 | 12.73 | 13.16 | 13.10 | 16.86 | 19.61 | 19.03 |
| Cost of Goods Sold Incl. D&A | 6.96 | 5.92 | 7.74 | 5.48 | 5.17 | 6.41 | 8.63 | 7.18 |
| Gross Profit | 0.63 | 2.67 | 5.00 | 7.68 | 7.93 | 10.45 | 10.98 | 11.86 |
| Selling, General and Administrative Excl. Other | 6.47 | 6.65 | 5.09 | 5.31 | 5.03 | 5.54 | 6.20 | 6.70 |
| Research and Development | 1.27 | 1.24 | 1.02 | 0.75 | 0.79 | 0.89 | 0.64 | 1.38 |
| Other Operating Expense | 0.00 | 0.00 | -0.31 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.84 | -3.98 | 0.21 | 2.07 | 2.90 | 4.92 | 4.79 | 5.15 |
| Interest Expense | 0.23 | 0.24 | 0.28 | 0.28 | 0.31 | 0.31 | 0.21 | 0.21 |
| Unusual Expense | 0.06 | -0.08 | 0.01 | -0.01 | 0.73 | 0.68 | 0.02 | 0.13 |
| Net Income Before Taxes | -5.75 | -4.26 | 0.15 | 1.84 | 2.27 | 3.94 | 4.67 | 4.84 |
| Income Taxes | 2.31 | -0.74 | -0.23 | 0.35 | 0.41 | 0.47 | 0.63 | 0.59 |
| Consolidated Net Income | -8.06 | -3.52 | 0.38 | 1.49 | 1.86 | 3.47 | 4.04 | 4.25 |
| Net Income From Continuing Operations | -6.75 | -2.99 | 0.32 | 1.25 | 1.56 | 2.91 | 3.39 | 3.56 |
| Net Income | -6.75 | -2.99 | 0.32 | 1.25 | 1.56 | 2.91 | 3.39 | 3.56 |
| EPS (Recurring) | -0.14 | -0.06 | 0.01 | 0.03 | 0.04 | 0.07 | 0.07 | 0.08 |
| EPS (Basic, Before Extraordinaries) | -0.14 | -0.06 | 0.01 | 0.03 | 0.03 | 0.06 | 0.07 | 0.08 |
| EPS (Diluted) | -0.14 | -0.06 | 0.01 | 0.03 | 0.03 | 0.06 | 0.07 | 0.08 |
| EBITDA | -3.92 | -2.29 | 1.99 | 3.61 | 4.53 | 6.63 | 6.26 | 6.47 |
| Non-Operating Income (Expense) | 0.39 | -0.12 | 0.23 | 0.04 | 0.42 | 0.02 | 0.11 | 0.02 |
| Price To Earnings Ratio | - | 100.34 | 111.09 | - | - | - | - | - |
| Price To Sales Ratio | 3.37 | 13.25 | - | - | - | - | - | - |
| Gross Margin | 8.30 | 31.10 | 39.25 | 58.37 | 60.55 | 62.00 | 56.00 | 62.30 |
| Operating Margin | -77.04 | -46.33 | 1.67 | 15.71 | 22.12 | 29.16 | 24.40 | 27.07 |
| Net Margin | -89.05 | -34.76 | 2.52 | 9.49 | 11.89 | 17.27 | 17.26 | 18.73 |
| Shares Outstanding | 47.39 | 47.39 | 47.17 | 47.17 | 47.17 | 47.17 | 47.17 | 47.17 |
| Market Capitalization | 45.18 | 282.93 | 313.26 | - | - | - | - | - |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|
| Cash & Short Term Investments | 7.43 | 2.75 | 4.01 | 1.40 | 0.99 |
| Short Term Receivables | 2.61 | 12.13 | 14.02 | 19.31 | 16.03 |
| Inventories | 5.92 | 9.45 | 8.65 | 8.32 | 7.11 |
| Other Current Assets | 3.71 | - | 1.68 | 1.79 | 1.75 |
| Total Current Assets | 19.66 | 24.33 | 28.35 | 30.83 | 25.88 |
| Net Property, Plant & Equipment | 33.95 | 34.96 | 37.13 | 39.59 | 38.66 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 6.74 | 2.03 | 2.30 | 4.01 | 3.26 |
| Deferred Tax Assets | 0.00 | 1.51 | - | - | - |
| Other Assets | 2.10 | 4.75 | 2.71 | 0.32 | 2.07 |
| Total Assets | 62.46 | 67.58 | 70.48 | 74.75 | 69.87 |
| Short Term Debt Incl. Current Port. of LT Debt | 9.43 | 11.18 | 11.26 | 7.90 | 4.71 |
| Accounts Payable | 6.30 | 5.89 | 6.44 | 11.40 | 12.17 |
| Income Tax Payable | 0.34 | 0.28 | 0.32 | 1.44 | 1.07 |
| Other Current Liabilities | 1.18 | 1.27 | 3.16 | 1.16 | 1.77 |
| Total Current Liabilities | 17.24 | 18.62 | 21.18 | 21.90 | 19.71 |
| Long Term Debt | 1.31 | 0.66 | 1.41 | 1.44 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 0.01 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.06 | 0.08 | 0.13 |
| Total Liabilities | 18.57 | 19.28 | 22.65 | 23.42 | 19.84 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 35.75 | 38.90 | 38.47 | 42.65 | 41.97 |
| Total Shareholders Equity | 35.75 | 38.90 | 38.47 | 42.65 | 41.97 |
| Accumulated Minority Interest | 8.14 | 9.40 | 9.37 | 8.68 | 8.06 |
| Total Equity | 43.89 | 48.30 | 47.84 | 51.34 | 50.03 |
| Total Liabilities & Stockholders Equity | 62.46 | 67.58 | 70.48 | 74.75 | 69.87 |
| Book Value Per Share | 0.75 | 0.82 | 0.82 | 0.90 | 0.89 |
| Tangible Book Value Per Share | 0.61 | 0.78 | 0.77 | 0.82 | 0.82 |
| Full-Time Employees | 269 | 277 | 275 | 294 | 276 |
| Price to Book Ratio | 2.01 | 1.28 | - | - | - |
| Return on Assets | -14.93 | 2.28 | 6.11 | 9.60 | - |
| Return on Equity | -26.01 | 4.06 | 10.95 | 16.40 | - |
| Return on Invested Capital | -26.19 | 3.97 | 11.13 | 15.74 | 14.39 |
| Quick Ratio | 0.80 | 0.80 | 0.93 | 1.03 | 0.95 |
| Current Ratio | 1.14 | 1.31 | 1.34 | 1.41 | 1.31 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|---|
| Net Income | -11.65 | -11.54 | 1.87 | 5.29 | 8.28 | 7.20 |
| Depreciation | 3.61 | 3.57 | 3.32 | 3.34 | 2.79 | 2.48 |
| Other Funds (Non Cash) | 2.06 | 2.04 | 0.52 | 0.98 | 1.62 | 0.55 |
| Funds from Operations | -4.42 | -4.38 | 5.84 | 9.69 | 12.50 | 10.16 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 6.29 | 6.24 | -0.14 | -2.86 | -9.92 | -5.23 |
| Income Taxes Payable | 0.04 | 0.04 | -0.03 | -1.09 | 0.47 | 0.12 |
| Cash from Operating Activities | 1.87 | 1.85 | 5.70 | 6.83 | 2.57 | 4.93 |
| Capital Expenditures | -1.77 | -1.76 | -3.86 | -1.64 | -4.06 | -4.09 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.02 | 0.15 | 0.00 | 0.02 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | -0.17 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | -0.17 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | -0.98 | -0.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.98 | 0.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -1.77 | -1.76 | -3.84 | -1.66 | -4.06 | -4.07 |
| Cash Dividends Paid | 0.00 | 0.00 | -2.23 | -5.57 | -3.18 | -1.71 |
| Change in Capital Stock | 6.25 | 6.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 6.25 | 6.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 6.25 | 6.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -1.99 | -1.68 | -0.38 | 3.49 | 5.18 | 1.24 |
| Change in Long Term Debt | - | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.02 | -0.02 | -0.47 | -0.63 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.02 | -0.02 | -0.49 | -0.63 | 0.00 | 0.00 |
| Cash from Financing Activities | 4.54 | 4.49 | -3.07 | -2.71 | 2.00 | -0.47 |
| Exchange Rate Effect | -0.18 | -0.18 | 0.02 | - | - | - |
| Net Change in Cash | 4.45 | 4.41 | -1.19 | 2.46 | - | - |
| Free Cash Flow | 1.73 | 1.71 | 3.82 | 5.79 | -1.48 | 1.98 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 31.50 | 31.76 | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 1.54 | 0.13 | 0.08 | -0.19 | -0.08 |
Balance sheet, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 7.43 | 6.65 | 2.75 | 1.17 | 4.01 | 3.24 |
| Short Term Receivables | 2.61 | 8.68 | 12.13 | 12.61 | 14.02 | 17.07 |
| Inventories | 5.92 | 9.20 | 9.45 | 10.16 | 8.65 | 7.79 |
| Other Current Assets | 3.71 | 3.59 | - | 1.47 | 1.68 | 1.76 |
| Total Current Assets | 19.66 | 28.11 | 24.33 | 25.42 | 28.35 | 29.86 |
| Net Property, Plant & Equipment | 33.95 | 34.43 | 34.96 | 35.00 | 37.13 | 36.70 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 6.74 | 2.14 | 2.03 | 2.28 | 2.30 | 3.60 |
| Deferred Tax Assets | 0.00 | 2.28 | 1.51 | - | - | - |
| Other Assets | 2.10 | 3.46 | 4.75 | 4.41 | 2.71 | 0.58 |
| Total Assets | 62.46 | 70.42 | 67.58 | 67.11 | 70.48 | 70.74 |
| Short Term Debt Incl. Current Port. of LT Debt | 9.43 | 11.31 | 11.18 | 12.03 | 11.26 | 10.99 |
| Accounts Payable | 6.30 | 5.97 | 5.89 | 5.73 | 6.44 | 6.74 |
| Income Tax Payable | 0.34 | 0.30 | 0.28 | 0.53 | 0.32 | 0.43 |
| Other Current Liabilities | 1.18 | 1.23 | 1.27 | 0.62 | 3.16 | 6.26 |
| Total Current Liabilities | 17.24 | 18.82 | 18.62 | 18.91 | 21.18 | 24.42 |
| Long Term Debt | 1.31 | 0.66 | 0.66 | 0.00 | 1.41 | 1.38 |
| Deferred Tax Liabilities | 0.01 | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.05 | 0.06 | 0.08 |
| Total Liabilities | 18.57 | 19.47 | 19.28 | 18.97 | 22.65 | 25.88 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 35.75 | 41.72 | 38.90 | 38.76 | 38.47 | 36.01 |
| Total Shareholders Equity | 35.75 | 41.72 | 38.90 | 38.76 | 38.47 | 36.01 |
| Accumulated Minority Interest | 8.14 | 9.23 | 9.40 | 9.38 | 9.37 | 8.85 |
| Total Equity | 43.89 | 50.95 | 48.30 | 48.14 | 47.84 | 44.86 |
| Total Liabilities & Stockholders Equity | 62.46 | 70.42 | 67.58 | 67.11 | 70.48 | 70.74 |
| Book Value Per Share | 0.75 | 0.88 | 0.82 | 0.82 | 0.82 | 0.76 |
| Tangible Book Value Per Share | 0.61 | 0.84 | 0.78 | 0.77 | 0.77 | 0.69 |
| Price to Book Ratio | 2.01 | 7.26 | 8.04 | - | - | - |
| Return on Assets | -14.98 | -3.88 | 2.27 | 4.07 | 6.15 | - |
| Return on Equity | -26.09 | -6.63 | 4.06 | 7.51 | 11.02 | - |
| Return on Invested Capital | -18.22 | -7.05 | 0.81 | 3.22 | 3.91 | 7.79 |
| Quick Ratio | 0.80 | 1.01 | 0.80 | 0.81 | 0.93 | 0.90 |
| Current Ratio | 1.14 | 1.49 | 1.31 | 1.34 | 1.34 | 1.22 |
Cash flow, quarterly
| Metric | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 |
|---|---|---|---|---|---|---|
| Net Income | -8.12 | -3.52 | 0.39 | 1.49 | 1.71 | 3.47 |
| Depreciation | 1.92 | 1.69 | 1.79 | 1.54 | 1.56 | 1.71 |
| Other Funds (Non Cash) | 1.48 | 0.58 | 1.42 | -0.90 | 0.47 | 0.50 |
| Funds from Operations | -2.43 | -1.99 | 3.55 | 2.30 | 3.86 | 5.63 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 6.23 | 0.06 | 0.12 | -0.26 | 1.68 | -4.49 |
| Income Taxes Payable | 0.02 | 0.02 | -0.25 | 0.22 | -0.08 | -0.99 |
| Cash from Operating Activities | 3.80 | -1.93 | 3.68 | 2.04 | 5.54 | 1.15 |
| Capital Expenditures | -1.68 | -0.09 | -1.68 | -2.19 | -1.44 | -0.16 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.02 | 0.00 | 0.15 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | -0.02 | -0.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.02 | 0.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -1.68 | -0.09 | -1.66 | -2.19 | -1.46 | -0.16 |
| Cash Dividends Paid | 0.00 | 0.00 | -0.03 | -2.20 | -2.85 | -2.60 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.11 | 6.14 | 0.07 | -0.07 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.11 | 6.14 | 0.07 | -0.07 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.11 | 6.14 | 0.07 | -0.07 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -1.41 | -0.29 | -0.04 | -0.35 | -0.18 | 3.60 |
| Change in Long Term Debt | - | - | - | - | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | - | - | - | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | - | - | - | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.00 | -0.02 | -0.47 | 0.00 | -0.62 | 0.00 |
| Other Financing Activities Uses | -0.00 | -0.02 | -0.49 | 0.00 | -0.62 | 0.00 |
| Cash from Financing Activities | -1.30 | 5.83 | -0.46 | -2.62 | -3.66 | 1.01 |
| Exchange Rate Effect | -0.09 | -0.09 | 0.02 | 0.00 | - | - |
| Net Change in Cash | 0.73 | 3.72 | 1.58 | -2.77 | - | - |
| Free Cash Flow | 3.69 | -1.96 | 2.03 | 1.80 | 4.68 | 0.98 |
| Price to Free Cash Flow | 31.50 | 8,967.66 | - | - | - | - |
Revenue breakdown
| Direct Sales Channel | 2024: 16.94M 2025: 7.22M |
|---|---|
| Distribution Network | 2024: 8.33M 2025: 8.56M |
| Government Tender And Procurement | 2024: 657.89K 2025: 412.42K |
| China | 2024: 25.93M 2025: 16.19M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.40% | 0.0M | 7.7M | 1.97M |
| 2026-10-15 | 0.88% | 0.1M | 7.7M | 5.55M |
| 2026-09-30 | 1.49% | 0.1M | 7.7M | 5.12M |
| 2026-09-15 | 1.78% | 0.1M | 7.7M | 5.20M |
| 2026-08-31 | 2.25% | 0.2M | 7.7M | 5.17M |
| 2026-08-14 | 4.70% | 0.4M | 7.7M | 5.21M |
| 2026-07-31 | 3.85% | 0.3M | 7.7M | 3.81M |
| 2026-07-15 | 0.74% | 0.1M | 7.7M | 102.73K |
| 2026-06-30 | 0.56% | 0.0M | 7.7M | 89.70K |
| 2026-06-15 | 1.41% | 0.1M | 7.7M | 276.59K |
| 2026-05-29 | 0.38% | 0.0M | 7.7M | 224.99K |
| 2026-05-15 | 0.77% | 0.0M | 4.4M | 225.90K |
| 2026-04-30 | 0.71% | 0.0M | 4.4M | 214.13K |
| 2026-04-15 | 1.15% | 0.1M | 4.4M | 215.26K |
| 2026-03-31 | 3.34% | 0.1M | 4.4M | 214.18K |
| 2026-03-13 | 0.29% | 0.0M | 4.4M | 16.46K |
| 2026-02-27 | 0.46% | 0.0M | 4.4M | 18.40K |
| 2026-02-13 | 0.51% | 0.0M | 4.4M | 20.77K |
| 2026-01-30 | 0.51% | 0.0M | 4.4M | 21.73K |
| 2026-01-15 | 0.48% | 0.0M | 4.4M | 30.79K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-08-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-06 | SEC |
| 2026-07-21 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
| 2026-06-25 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-25 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-25 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-25 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-25 | 3 | Initial statement of beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-04 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-04 | SEC |
| 2026-04-28 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2025-12-31 | SEC |
| 2026-04-24 | 3 | Initial statement of beneficial ownership of securities | 2026-03-24 | SEC |
| 2026-04-24 | 3 | Initial statement of beneficial ownership of securities | 2026-03-24 | SEC |
| 2026-03-25 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-24 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-18 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-02 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-27 | SEC |
| 2026-02-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-02-23 | SEC |
| 2025-12-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-06-30 | SEC |
| 2025-10-22 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2025-10-22 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2025-07-03 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2024-12-31 | SEC |
| 2025-05-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-05-23 | SEC |
| 2025-04-29 | NT 20-F | 2024-12-31 | SEC | |
| 2025-04-03 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-04-02 | SEC |
| 2025-03-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-03-06 | SEC |
| 2025-02-21 | SCHEDULE 13G | SEC | ||
| 2025-01-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-01-14 | SEC |
| 2025-01-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2025-01-08 | SEC |
| 2025-01-07 | 424B4 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| XTX Topco Ltd | 0.16% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.10% |
| StoneX Group Inc. | 0.06% |
| WINTON GROUP Ltd | 0.04% |
| UBS Group AG | 0.01% |
| ROYAL BANK OF CANADA | 0.00% |
| MORGAN STANLEY | 0.00% |
| JPMORGAN CHASE & CO | 0.00% |
| Caitong International Asset Management Co., Ltd | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 0.03% |
OakChart. ZYBT. Cached 15 minutes.
Some panels did not load: ratings, insider, news.